Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Receives CE Marking for Two Colorectal Cancer Dx Assays

NEW YORK (GenomeWeb) – VolitionRx announced today that it has received CE marking for two of its blood-based diagnostic assays for colorectal cancer.

The tests, NuQ V001 and NuQ T003, are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts. Last September, the company received CE marking for the NuQ X001S biomarker assay for colorectal cancer detection.

NuQ V001 and NuQ X001S target specific epigenetic cancer signals within the nucleosome, while the NuQ T003 test targets the whole nucleosome. The company said it intends to market a commercial test for colorectal cancer that includes a panel of four to six individual NuQ biomarker assays by the end of 2016.

Clinical testing of additional biomarker assays are ongoing, VolitionRx added. The company also aims to introduce its assays for clinical use in the US, but did not provide a timeframe for market launch.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.